AMRUTANJAN · Amrutanjan Health Care Ltd · Biotechnology & Drugs
AMRUTANJAN · Amrutanjan Health Care Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
31.0% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹103 Cr
Revenue YoY
PAT YoY
-47.4%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
3.9
P/S (TTM)
2.8
Sector P/E
36.3
Dividend yield
+1.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| AMRUTANJAN (this stock) | 29.3 | 3.9 | +10.6% | +14.6% | 0 | +1.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
5.82% (-1.20pp)
falling 2q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-08-20 | AMRUTANJAN | 0 | 0 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: Amrutanjan Health Care Limited's investor presentation for the quarter ended June 30, 2026, reported a 9.48% growth in net sales, reaching ₹102.97 crores compared to ₹94.05 crores in the same quarter last year. The women's hygiene segment showed robust growth, with a 27.09% increase in net sales, while the pain management category faced a decline of 3.4% in volume growth. Management highlighted that 65% of revenue comes from pain management, which has been impacted by retailer demand erosion and high base effects. New product launches, including women's and men's razors, contributed to overall sales, and a new sanitary napkin manufacturing facility was commissioned in Telangana. Management noted that one-time charges from the previous year would not recur, and they expressed confidence in achieving double-digit growth in revenue and operating profits for the year.
The presentation included both positive growth metrics and challenges in key segments.
Sourced from an exchange-filed presentation, dated 12 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Amrutanjan Health Care Limited (AHCL) provided an investor presentation detailing its performance for the quarter and year ended March 31, 2026. The presentation highlighted a 10.60% growth in net sales for Q4 FY26, with significant contributions from the Pain Management and Women’s Hygiene segments, which saw double-digit growth. Management reported that the Pain Management portfolio, particularly the Back Pain Roll On and Maha Strong products, drove this growth. New product launches included personal care items and ortho pain relief products, which received positive market acceptance. The company emphasized its strategic objectives, including expanding distribution and increasing brand visibility through marketing initiatives. Management noted a one-time charge related to a legal case and the impact of new Labour Codes on financials. Overall, the company reported a strong operational performance with a focus on digitization and efficiency improvements.
Management emphasized strong growth and operational improvements.
Sourced from an exchange-filed presentation, dated 09 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Amrutanjan Health Care Limited (AHCL) reported its investor presentation for the quarter and nine months ended December 31, 2025. The presentation highlighted a 14.90% growth in net sales for Q3 FY26, with the OTC business (excluding Comfy) growing by 14.3% and the Comfy brand by 22.6%. For the nine-month period, the OTC business grew by 14.6%, while profits before tax increased by 18%. Management noted that the Pain Management segment, particularly the Amrutanjan brand, continued to show strong performance, with double-digit growth driven by products like Back Pain Roll On and Maha Strong. The company also launched Comfy Slimfit XXL night pads and expanded its rural market coverage through various initiatives. Management set a goal of adding 100,000 chemists in specific markets, achieving a new outlet base of 40,000. Overall, the presentation emphasized strong execution and growth across key segments.
Management emphasized strong growth and execution across various business segments.
Sourced from an exchange-filed presentation, dated 04 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedAmrutanjan Health Care Limited's FY2025-26 annual report highlights a strategic focus on execution, distribution expansion, and digital transformation. The company expanded its chemist network significantly, added 44,000 new outlets, and plans to add 100,000 more by FY2027. It emphasized digitizing operations, achieving 68% digitization with plans to reach 85% through new systems. The report also noted investments in manufacturing capacity, including a new sanitary pad plant set to launch in FY2027, and a commitment to corporate social responsibility through various charitable initiatives. Governance and risk management frameworks were strengthened, with regular evaluations of board performance and internal controls.
- Focused execution and distribution expansion with 44,000 new chemist outlets added in FY2026.
- Digitization efforts management targets 85% completion through new systems like Distributor Management System (DMS) and SAP TM.
- Capacity expansion plans including a new sanitary pad manufacturing plant in FY2027.
- Corporate social responsibility initiatives with significant contributions to various charitable organizations.
- Strengthened corporate governance with regular board evaluations and internal control assessments.
Key takeaway: Amrutanjan Health Care Limited is prioritizing focused execution, digital transformation, and capacity expansion to drive growth, supported by a robust corporate governance framework and active community engagement.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item); Default / Covenant Breach (5 items); Investigation or enforcement mention (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The auditor issued a qualified opinion on the financial statements of Amrutanjan Health Care Limited for the year ended March 31, 2023.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company has not complied with the SEBI (Prohibition of Insider Trading) Regulations, 2015 regarding maintaining a Structured Digital Database (SDD) as required by Regulation 2(n) read with Regulation 3(5).
Default / Covenant Breach
5 occurrencesRecent (last 12 months)
The company has undisputed statutory dues in arrears for more than six months as of March 31, 2026, including Goods and Service Tax, Income-Tax, and other statutory dues.
Earlier (1-3 years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2025, specifically related to Income-Tax and Goods and Services Tax.
The company has statutory dues in arrears for more than six months as of 31 March 2024, including income tax disputes with various authorities.
Older (3+ years ago)
The company has undisputed statutory dues in arrears for more than six months as of March 31, 2023, including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, or Cess.
AMRUTANJAN HEALTH CARE LIMITED has undisputed statutory dues in arrears for more than six months as of March 31, 2022, including GST, provident fund, employees state insurance, income tax, duty of customs, cess, and other statutory dues.
Investigation or enforcement mention
2 occurrencesEarlier (1-3 years ago)
The company received an anonymous whistleblower complaint in 2022-2023 alleging lapses by senior management employees, including undue enrichment and conflicts of interest. The company initiated a forensic audit by Deloitte Touche Tohmatsu India LLP and later engaged PKF Sridhar & Santhanam LLP to investigate the findings.
Older (3+ years ago)
The auditors drew attention to a whistle blower complaint received by the company, leading to the appointment of Deloitte Touche Tohmatsu India LLP to conduct a forensic investigation.
Routine disclosures
Internal Control Weakness
1 occurrenceOlder (3+ years ago)
The auditor of Amrutanjan Health Care Limited has identified a material weakness in the company's internal financial controls as of March 31, 2023.
Contingent Liability
6 occurrencesRecent (last 12 months)
AMRUTANJAN HEALTH CARE LIMITED has contingent liabilities related to claims not acknowledged as debts, including sales tax, service tax, goods and service tax, income tax matters, and other matters, pending resolution of proceedings. The company has disclosed these as contingent liabilities in its financial statements.
Earlier (1-3 years ago)
The Company has contingent liabilities related to income tax litigations, as mentioned in note 3(M), 3(R), 18 and 34.
The company has provision for income tax litigations and related contingent liabilities, as mentioned in note 3(M), 3(R), and 35 of the financial statements.
Older (3+ years ago)
The company has contingent liabilities including claims not acknowledged as debts, sales tax matters, Goods and Service Tax, income tax matters, and other matters, with pending resolution of proceedings and no practicable estimate of cash outflows.
The company has contingent liabilities related to pending litigations and sales tax, income tax, and other matters, with the outcome not expected to have a materially adverse effect on its financial position.
The company has contingent liabilities related to pending litigation and tax matters, with amounts not specified, and has made provisions where required.
Statutory dues in dispute
1 occurrenceOlder (3+ years ago)
The company has not deposited dues of duty of excise, service tax, and sales tax with the appropriate authorities due to disputes.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.3% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).